Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Meningioma 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoid Tumor 2Prostatic Neoplasms 1Neuroblastoma 1Neoplasms 1Ganglioneuroma 1Ganglioneuroblastoma 1Disease 1Carcinoma, Medullary 1Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

Everolimus 3Capecitabine 3lutetium Lu 177 dotatate 2lenvatinib 2cabozantinib 2Thyroidectomy 2Temozolomide 2Sorafenib 2Magnetic Resonance Spectroscopy 2High-Energy Shock Waves 2veliparib 1vatalanib 1vandetanib 1temsirolimus 1selpercatinib 1sacubitril and valsartan sodium hydrate drug combination 1ponatinib 1pentetreotide 1pasireotide 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine 1Vinorelbine 1Thalidomide 1Surgical Procedures, Operative 1Sunitinib 1Specimen Handling 1Sirolimus 1Semaxinib 1Restraint, Physical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Medullary × Ga(III)-DOTATOC × Clear all
NCT02174679 2020-07-27

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Jonsson Comprehensive Cancer Center

No longer available
EndocrineNET

Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡